Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 2/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 9/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 8/20 | 0.35 |
| ▸ | GAK | O14976 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.34 |
| ▸ | MET | P08581 | 1/20 | 0.34 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26549412 | 1.00 | TOP1 (0.35) | TOP1GRIN2BGRIN1GAKMAOB | |
| SCHEMBL26549409 | 0.94 | TOP1 (0.41) | TOP1GRIN2BGRIN1GAKMAOB | |
| SCHEMBL26549124 | 0.94 | TOP1 (0.41) | TOP1GRIN2BGRIN1GAKMAOB | |
| SCHEMBL26570615 | 0.94 | GRIN1 (0.35) | TOP1GRIN2BGRIN1GAKMAOB | |
| SCHEMBL26549280 | 0.92 | MET (0.34) | TOP1GRIN2BGRIN1GAKMAOB | |
| SCHEMBL26548082 | 0.91 | TOP1 (0.37) | TOP1MAOBSUCNR1PGRTDP1 | |
| SCHEMBL26548457 | 0.91 | TOP1 (0.37) | TOP1MAOBSUCNR1PGRTDP1 | |
| SCHEMBL26548954 | 0.90 | TOP1 (0.36) | TOP1MAOBSUCNR1PGRTDP1 | |
| SCHEMBL26548628 | 0.90 | TOP1 (0.36) | TOP1MAOBSUCNR1PGRTDP1 | |
| SCHEMBL26549119 | 0.87 | ALOX5 (0.41) | GRIN2BGRIN1GAKMETPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230337527-A1 | ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME | LAPTO CO., LTD. (KR) | 2023-10-19 | — | — | US | disclosed |
| US-20230337527-A1 | ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME | LAPTO CO., LTD. (KR) | 2023-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230337527-A1 | ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME | AOC1, ODC1, PIEZO1 | TOP1 1472/4885GRIN2B 2102/4885GRIN1 957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.